The new facility could buy stakes in, or offer loans to, companies in sectors such as healthcare, space, defence, digital and green technologies.

Rolled Euro banknotes are placed on US Dollar banknotes in this illustration taken May 26, 2020.
Rolled Euro banknotes are placed on US Dollar banknotes in this illustration taken May 26, 2020. (Reuters)

The European Commission has proposed setting up a $16.6 billion fund to invest in strategic companies that have been weakened by the Covid-19 crisis.

The proposal, which needs to be approved by EU governments and lawmakers, comes after firms worldwide became vulnerable to hostile takeovers as share prices fell and there were fewer funding opportunities during the coronavirus crisis.

The new facility could buy stakes in, or offer loans to, strategic companies in sectors such as healthcare, space, defence, digital and green technologies, EU industry commissioner Thierry Breton told a news conference on Friday.

Concerns over the vulnerability of some European companies grew in March after reports that the United States administration was looking into gaining access to Germany-based CureVac, a biotech firm working on a new technology that could slash costs for vaccines. The EU Commission reacted by promising $89.1 million to CureVac.

The EU financial support would go to companies "that need more capital to continue their expansion," Breton said, adding that it would also allow firms to shun help from unwanted partners.

The new fund is tiny compared to large sovereign wealth funds which have hundreds of billions of dollars to invest in strategic firms. However, its financial firepower is expected to be boosted by attracting private investors with guarantees.

The commission estimates that the $16.71 billion, which will be borrowed on financial markets, "could generate investments of up to 150 billion euros" in the 2021 to 2027 period, an EU document said.

The fund is part of a wider EU plan to back companies in need of financial capital support.

Other proposals include a $28.96 billion "solvency instrument" that would provide temporary support to healthy companies hit by the Covid-19 crisis and a $17 billion fund that would invest in smaller firms and companies active in infrastructure, research and social issues.

Source: Reuters